Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND... by Stephen B Hanauer, William J Sandborn, Christian Dallaire, André Archambault, Bruce Yacyshyn, Chyon Yeh, Nancy Smith-Hall

Get full text

Cytomegalovirus Isolated to a Colon Polyp in a Patient with Ulcerative Colitis on Ozanimod: A Case Report by Zehra Naseem, Ahmed Nadeem, Aidan J. David, Aun Muhammad, Fatima Zehra Shah, Brian M. Fung, Stephen B. Hanauer, Joseph David

Get full text

Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events by Franck Carbonnel, Anusha Shirwaikar Thomas, Julie R Brahmer, John A Thompson, Yinghong Wang, Hao Chi Zhang, Bret Lashner, Michel Obeid, Stephen B Hanauer, Malek Shatila, Antonio Pizuorno Machado, Sidra Naz, Nitish Mittal, Christine Catinis, Krishnavathana Varatharajalu, Carolina Colli Cruz, Eric Lu, Deanna Wu, Bryan Schneider, David P Farris

Get full text

The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program by Stephen B. Hanauer, Esther A. Torres, Patricia Aragon-Han, Jonathon C. Chapman, Arun C. Swaminath, Ronen Arai, Mandalina Butnariu, Thomas C. Lee, Shervin Rabizadeh, Morgan Check, Terrence A. Barrett, Jana G. Hashash, Thomas Meister, Eugene F. Yen, Jami Kinnucan, Daniel J. Stein, David Ziring, Rimma Shaposhnikov, Preetika Sinh, Taha M. Qazi, Andres J. Yarur, Farah Monzur, Thierry Dervieux, Bincy P. Abraham

Get full text